Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Debt (2018 - 2021)

Rein Therapeutics (RNTX) has disclosed Total Debt for 3 consecutive years, with $384000.0 as the latest value for Q1 2021.

  • On a quarterly basis, Total Debt changed N/A to $384000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $384000.0, a N/A change, with the full-year FY2020 number at $387000.0, changed N/A from a year prior.
  • Total Debt was $384000.0 for Q1 2021 at Rein Therapeutics, down from $387000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $5.3 million in Q4 2018 to a low of $384000.0 in Q2 2020.
  • A 3-year average of $2.2 million and a median of $387000.0 in 2020 define the central range for Total Debt.